Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen EVENITY (romosozumab-aqqg by Year
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)
Amgen EVENITY (romosozumab-aqqg: $2,100M in FY2025, up 34.4% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,100 | +34.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,563 | +34.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,160 | +47.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 787 | +48.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 530 | +51.4% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 350 | +85.2% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 189 | – | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
Breakdown
What makes up EVENITY (romosozumab-aqqg
- EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — U.S. product sales ($M)1,600 · FY2025
- EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M)500 · FY2025
- EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)34.0% · FY2025
Cite this data
StockData. (2026). Amgen EVENITY (romosozumab-aqqg ($M), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-evenity-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.